Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes
See a new #breastcancer activity via @PeerView @DrSGraff #MedEd